{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:06:08Z","timestamp":1790197568616,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.pcad.2009.11.002","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T10:13:54Z","timestamp":1262772834000},"page":"326-335","source":"Crossref","is-referenced-by-count":82,"title":["Anderson-Fabry Disease and the Heart"],"prefix":"10.1016","volume":"52","author":[{"given":"Constantinos","family":"O'Mahony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2009.11.002_bib1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.11.002_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Schafer","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pcad.2009.11.002_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pcad.2009.11.002_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pcad.2009.11.002_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","article-title":"Disease manifestations and X inactivation in heterozygous females with Fabry disease","volume":"95","author":"Maier","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","article-title":"Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease","volume":"60","author":"Altarescu","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.pcad.2009.11.002_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.gim.0000200950.25118.dd","article-title":"Quantitative dysmorphology assessment in Fabry disease","volume":"8","author":"Ries","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00439-005-1300-5","article-title":"Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes","volume":"117","author":"Matsuzawa","year":"2005","journal-title":"Hum Genet"},{"key":"10.1016\/j.pcad.2009.11.002_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","article-title":"Structure-function relationships in alpha-galactosidase A","volume":"96","author":"Garman","year":"2007","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2009.11.002_bib15","first-page":"271","article-title":"An association study of inflammatory cytokine gene polymorphisms in Fabry disease","volume":"17","author":"Safyan","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.pcad.2009.11.002_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.002_bib17","series-title":"The metabolic and molecular bases of inherited disease","first-page":"37","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.pcad.2009.11.002_bib18","first-page":"32","article-title":"Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy","volume":"21","author":"Breunig","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.pcad.2009.11.002_bib19","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.11.002_bib20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib22","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib23","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1161\/CIRCULATIONAHA.105.593558","article-title":"Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study","volume":"113","author":"Morita","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/heart.89.8.929","article-title":"Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy","volume":"89","author":"Ommen","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2009.11.002_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2009.11.002_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2009.11.002_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2002.tb03110.x","article-title":"Pathophysiology and assessment of neuropathic pain in Fabry disease","volume":"91","author":"Schiffmann","year":"2002","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib30","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/archderm.140.12.1526","article-title":"Fabry disease: more than angiokeratomas","volume":"140","author":"Mohrenschlager","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.pcad.2009.11.002_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200304030-00005","article-title":"Fabry disease: recognition and management of cutaneous manifestations","volume":"4","author":"Mohrenschlager","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.pcad.2009.11.002_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pcad.2009.11.002_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pcad.2009.11.002_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry's disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pcad.2009.11.002_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.pcad.2009.11.002_bib37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","article-title":"Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases","volume":"92","author":"Elleder","year":"2003","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","article-title":"Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts","volume":"82","author":"Lucke","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2009.11.002_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00001573-200105000-00008","article-title":"Mitochondria and the heart","volume":"16","author":"Hirano","year":"2001","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2009.11.002_bib41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2009.11.002_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin Genet"},{"issue":"Suppl 2","key":"10.1016\/j.pcad.2009.11.002_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","article-title":"Cardiac manifestations in Fabry disease","volume":"24","author":"Linhart","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2009.11.002_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-0736(82)80010-1","article-title":"Electrocardiograms in Fabry's disease","volume":"15","author":"Sheth","year":"1982","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","article-title":"Cardiac manifestations of Anderson-Fabry disease in children and adolescents","volume":"97","author":"Kampmann","year":"2008","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.pcad.2009.11.002_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/euhj.2000.2399","article-title":"New normal limits for the paediatric electrocardiogram","volume":"22","author":"Rijnbeek","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2009.11.002_bib47","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","article-title":"Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization","volume":"47","author":"Pieroni","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib48","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2008.02.046","article-title":"The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy","volume":"51","author":"Kounas","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1475-097X.2008.00851.x","article-title":"Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance","volume":"29","author":"Koskenvuo","year":"2009","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.pcad.2009.11.002_bib50","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2009.11.002_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib52","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/hrt.2004.035584","article-title":"The natural history of left ventricular systolic function in Anderson-Fabry disease","volume":"91","author":"Shah","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.hco.0000131534.25034.43","article-title":"Tissue Doppler imaging in Fabry disease","volume":"19","author":"Pieroni","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib55","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2009.11.002_bib56","doi-asserted-by":"crossref","first-page":"W97","DOI":"10.2214\/AJR.08.1201","article-title":"Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy","volume":"192","author":"De Cobelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.pcad.2009.11.002_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","article-title":"The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease","volume":"8","author":"Moon","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.pcad.2009.11.002_bib58","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0735-1097(03)00189-X","article-title":"Toward clinical risk assessment inhypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance","volume":"41","author":"Moon","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib59","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2006.07.088","article-title":"Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease","volume":"99","author":"Kawano","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0002-9149(94)90106-6","article-title":"Electrophysiologic findings in Fabry's disease with a short PR interval","volume":"74","author":"Pochis","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"Lobo","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.pcad.2009.11.002_bib63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib64","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1161\/CIRCULATIONAHA.107.723387","article-title":"Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue","volume":"116","author":"Frustaci","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib65","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000047318","article-title":"Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Review of cardiovascular manifestations","volume":"94","author":"Eckart","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.pcad.2009.11.002_bib66","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.pcad.2009.11.002_bib67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10545-008-0794-0","article-title":"Intravascular ultrasound assessment of coronary artery involvement in Fabry disease","volume":"31","author":"Kovarnik","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2009.11.002_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/08035320510028760","article-title":"Vascular complications of Fabry disease: enzyme replacement and other therapies","volume":"94","author":"Hughes","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.pcad.2009.11.002_bib70","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.humpath.2007.07.001","article-title":"Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries","volume":"38","author":"Chimenti","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pcad.2009.11.002_bib71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8175.2005.03191.x","article-title":"Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male","volume":"22","author":"Magage","year":"2005","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2009.11.002_bib73","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0195-668X(03)00479-2","volume":"24","author":"Maron","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2009.11.002_bib74","first-page":"81","article-title":"Cardiac transplantation for Fabry's disease","volume":"14","author":"Cantor","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib75","doi-asserted-by":"crossref","first-page":"L1189","DOI":"10.1152\/ajplung.2001.281.5.L1189","article-title":"Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes","volume":"281","author":"Baritussio","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pcad.2009.11.002_bib76","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1161\/CIRCUALTIONAHA.108.189742","volume":"117","author":"Epstein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib77","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2009.11.002_bib78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.pcad.2009.11.002_bib79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pcad.2009.11.002_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.11.002_bib82","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.11.002_bib83","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2009.11.002_bib84","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of agalsidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pcad.2009.11.002_bib85","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","article-title":"Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study","volume":"95","author":"Imbriaco","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.11.002_bib86","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib87","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.11.002_bib88","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2009.11.002_bib89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","article-title":"Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters","volume":"31","author":"Koskenvuo","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.pcad.2009.11.002_bib90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T23:26:38Z","timestamp":1558740398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062009000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0033062009000929"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2009.11.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}